Janssen Pharmaceutica Nv

Concert Pharmaceuticals, Inc.

Yumanity Therapeutics, Inc.

Sun Pharmaceutical Industries Limited

Bhaumik Pandya

Iwona Wrona

Kerem Ozboya

Bertrand Le Bourdonnec

Matthew Lucas

Parcharee Tivitmahaisoon

Daniel Tardiff

Roger D Tung

Kenneth Rhodes

Robert Scannevin

Jeff Piotrowski

Rebecca Aron

Craig E Masse

Scott L Harbeson

Matthew C Lucas

Benjamin Vincent

Eric Solis

Chee-Yeun Chung

Ian Robert Silverman

Julie Fields Liu

I Robert Silverman

Adam J Morgan

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Compounds and uses thereof

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression. Patients that may be treated using the compositions and methods described herein include those that express a mutant TDP-43 isoform containing a mutation associated with TDP-43-promoted aggregation and toxicity.

Compositions and methods for the treatment and prevention of neurological disorders

This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).

Derivatives of pyrazole-substituted amino-heteroaryl compounds

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentifylline and related compounds are beneficial.

Substituted xanthine derivatives

The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.

Deuterated derivatives of ruxolitinib

Growing community of inventors

Bedford, MA, United States of America

Bhaumik Pandya